The 18 most recent market catalysts affecting $CAH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 65
RBC Capital Initiates Coverage On Cardinal Health with Outperform Rating, Announces Price Target of $276
RBC Capital's initiation of coverage on Cardinal Health (CAH) with an 'Outperform' rating and a $276 price target is a positive development for the company. This action indicates t…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $275
Barclays analyst Glen Santangelo maintained an 'Overweight' rating on Cardinal Health (CAH) and raised the price target from $258 to $275. This action indicates that a prominent fi…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on Cardinal Health, Raises Price Target to $270
Evercore ISI Group's analyst Elizabeth Anderson has maintained her 'Outperform' rating for Cardinal Health (CAH) and raised the price target by $5 to $270. This action signals cont…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $265
Morgan Stanley analyst Erin Wright maintained an 'Overweight' rating on Cardinal Health (CAH) and raised the price target from $255 to $265. This action signals a continued positiv…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Cardinal Health, Raises Price Target to $250
Mizuho analyst Steven Valiquette maintained an 'Outperform' rating on Cardinal Health (CAH) and raised the price target from $240 to $250. This action signals continued analyst con…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Cardinal Health, Raises Price Target to $277
Wells Fargo analyst Stephen Baxter maintained an 'Overweight' rating on Cardinal Health (CAH) and raised the price target from $245 to $277. This action signals a strong vote of co…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Baird Maintains Outperform on Cardinal Health, Raises Price Target to $274
Baird analyst Eric Coldwell maintained an 'Outperform' rating on Cardinal Health (CAH) and raised the price target from $251 to $274. This action signals increased confidence from …
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 92
Cardinal Health Says It Now Exclusively Serves Nearly Half The Cell-And-Gene Therapy Market
Cardinal Health (CAH) delivered a strong Q4 earnings beat on adjusted EPS and, more importantly, issued an optimistic fiscal 2027 earnings outlook that surpassed analyst expectatio…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 85
Cardinal Health shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results and announced a $5 billion stock buyback.
The headline indicates a strong corporate catalyst for Cardinal Health (CAH). Better-than-expected Q4 adjusted EPS signals operational efficiency and profitability, while the $5 bi…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 65
US Stocks Mixed; Cardinal Health Shares Jump After Q4 Results
The filing details a mixed day for US equities, with the Dow and S&P 500 up, while the NASDAQ was down. The most significant individual company news is Cardinal Health's Q4 earning…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
Cardinal Health Announces $5B Incremental Share Buyback Authorization
Cardinal Health's Board of Directors approved a substantial $5.0 billion increase to its share repurchase program, raising the total authorization to $6.4 billion through August 20…
Aug 11, 2026
Corporate Catalyst
Neutral
Impact 75
Cardinal Health Q4 Adj. EPS $2.91 Beats $2.42 Estimate, Sales $63.672B Miss $65.029B Estimate
Cardinal Health's Q4 results show a strong adjusted EPS beat, suggesting effective cost management and profitability despite a revenue miss. This mixed performance could lead to in…
Aug 11, 2026
Corporate Catalyst
Neutral
Impact 75
Cardinal Health Sees FY2027 Adj EPS $12.40-$12.60 vs $12.04 Est
Cardinal Health (CAH) has released its adjusted EPS guidance for fiscal year 2027, forecasting earnings between $12.40 and $12.60 per share. This projection significantly exceeds t…
Aug 11, 2026
Corporate Catalyst
Neutral
Impact 65
Cardinal Health Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
The filing details analyst expectations for Cardinal Health's Q4 earnings, with consensus estimates showing growth in both EPS and revenue year-over-year. Several prominent analyst…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Cardinal Health, Raises Price Target to $265
Citigroup analyst Daniel Grosslight maintained a 'Buy' rating on Cardinal Health (CAH) and raised the price target from $245 to $265. This action indicates a positive outlook from …
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Cardinal Health, Raises Price Target to $240
Mizuho analyst Steven Valiquette maintained an 'Outperform' rating for Cardinal Health and raised the price target from $235 to $240. This action signals a continued positive senti…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 92
Cardinal Health To Acquire The Diabetes Health Business Of Adapthealth And, In Its Entirety, Strive Medical For ~$360M In Cash
Cardinal Health (CAH) announced the acquisition of AdaptHealth's (AHCO) Diabetes Health business and Strive Medical for $360 million in cash. This move significantly bolsters Cardi…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Cardinal Health, Raises Price Target to $274
UBS analyst Kevin Caliendo maintained a 'Buy' rating on Cardinal Health (CAH) and raised the price target from $260 to $274. This action signals continued bullish sentiment from a …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.